Artificial intelligence is likely to play a crucial role in medical supply chain management and continue to transform product development, but FDA officials say strong agency oversight is needed to protect the long-term success of industries.
The FDA will continue to play a central role in evaluating AI tools to improve health-care and biomedicine, but all involved entities will need to be equipped with the rigor that the transformative technology merits, high-ranking officials for the Food and Drug Administration wrote Tuesday in a JAMA Network Special Communication.
The analysis reviewed the history of the FDA’s AI regulation and outlined ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.